Video

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Heinz-Josef Lenz, MD, FACP, professor of medicine, J. Terrance Lanni Chair in Gastrointestinal Cancer Research, and co-director, University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability—high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Immunotherapy can lead to high responses in patients with MSI-H/dMMR mCRC, but the durability of these responses has not been well described. The 2-year follow-up results from the CheckMate-142 trial showed that these patients can achieve robust and durable responses with the combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) in the frontline setting.

Notably, the objective response rate increased from 60% to 69%, and the complete response rate increased from 7% to 13%. These responses compare very favorably to historical rates in the newly diagnosed setting, concludes Lenz.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System